II2 Stock Overview
A medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InspireMD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.40 |
| 52 Week High | US$3.12 |
| 52 Week Low | US$1.70 |
| Beta | 0.93 |
| 11 Month Change | 5.26% |
| 3 Month Change | -5.51% |
| 1 Year Change | 10.09% |
| 33 Year Change | -25.47% |
| 5 Year Change | -81.29% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| II2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.0% | -2.5% | -1.3% |
| 1Y | 10.1% | -8.4% | 7.4% |
Return vs Industry: II2 exceeded the German Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: II2 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| II2 volatility | |
|---|---|
| II2 Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: II2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: II2's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 80 | Marvin Slosman | www.inspiremd.com |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.
InspireMD, Inc. Fundamentals Summary
| II2 fundamental statistics | |
|---|---|
| Market cap | €65.69m |
| Earnings (TTM) | -€26.94m |
| Revenue (TTM) | €6.51m |
9.9x
P/S Ratio-2.4x
P/E RatioIs II2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| II2 income statement (TTM) | |
|---|---|
| Revenue | US$6.82m |
| Cost of Revenue | US$5.28m |
| Gross Profit | US$1.54m |
| Other Expenses | US$29.78m |
| Earnings | -US$28.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 22.61% |
| Net Profit Margin | -413.96% |
| Debt/Equity Ratio | 0% |
How did II2 perform over the long term?
See historical performance and comparison